biomedical polyypurethane developed within the custom-imd ... imd... · smithers rapra...

38
Biomedical Polyurethane Developed Within the Custom-IMD ProjectDr Steve Rowlands Dr Steve Rowlands. Smithers Rapra Technology Smithers Rapra Technology .

Upload: others

Post on 08-Oct-2020

5 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

“Biomedical Polyurethane Developed Within y pthe Custom-IMD Project”

Dr Steve RowlandsDr Steve Rowlands.

Smithers Rapra TechnologySmithers Rapra Technology.

Page 2: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

ContentsContents

1. Introduction to the Custom IMD Project.

2. Polyurethane for a Spinal Nucleus Prosthesis.

3. Summary.

2

Page 3: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

IntroductionCustom-IMD is a 6th Framework programme funded in part by the EU. p y

There are three main case studies within mCustom-IMD.

1. Cranio-facial bone plate prosthetic,

2 S i l l b l h i2. Spinal lumbar nucleus prosthetic,

3. Dental restoration.

3

Page 4: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Project OverviewProject OverviewObjective: development of the complete e-supply chain for the j pm f mp pp y frealization of custom implants and to demonstrate those through the 3 applications :

Materials development Data acquisitionAreas of work include:

Materials development

“Rapid” Manufacturing

Data acquisition

Implant designRapid Manufacturing

Biocompatibility

p g

e Supply chainwww.CustomIMD.eu

e-Supply chain

Page 5: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Project Overview: The NumbersProject Overview: The Numbers

Budget: € 9 8M with € 5 4M of EU funding• Budget: € 9,8M with € 5,4M of EU funding• Duration: 48 months (from 01.02.07 to 31.01.11)• Partners: 23

– RTD: 4– SME: 16SME: 16– University Hospital: 2– Centre of excellence: 1

• Countries: 7– Belgium

G S it l d– Germany -Switzerland– Netherlands -Spain– Poland -United Kingdom

5an n t K ng m

Page 6: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Polyurethanes for Spinal Disc RestorationRestoration

The spinal implant investigation focuses The spinal implant investigation focuses on a nucleus implant for the lumbarregion only.

Polyurethane development and Polyurethane development and Optimisation studies have been targeted for the Spinal Nucleus g pImplant.

Specific Mechanical, Chemical and Material properties were therefore Material properties were therefore required.

Page 7: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Why a Spinal Nucleus Implant?W y p mpDegenerative disc disease refers to a syndrome

i hi h i d di l b k i in which a compromised disc causes low back pain.

The pain is also frequently caused by simple wear and tear on the spine.

Degenerative disc disease is fairly common, and it is estimated that at least 30% of people aged is estimated that at least 30% of people aged 30-50 years old will have some degree of disc space degeneration.

Page 8: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Examples of Spinal Disc ProblemsExamples of Spinal Disc Problems

Page 9: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Polyurethane for a Spinal Nucleus ProstheticNucleus Prosthetic

Nucleus PulposusFc

Annulus fibrosis

Fc = Compressive Forcep

Page 10: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Kinematics of the Natural DiscIn order to reproduce physiological kinematic behaviour the following

it i t b b d

Kinematics of the Natural Disc

criteria must be observed:

6 degrees of freedom.

(3 translations and 3 rotations) Y

Allow movement without exceeding the natural range of movement.

Avoiding implant migration.

Floating centre of rotation as in the X

Z

Floating centre of rotation as in the natural spine.

Maintain disc height during 6 degrees of spinal motion

www.CustomIMD.eu

Maintain disc height during motion.

Page 11: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Dynamics and Endurance of the Natural Disc

The maximum expected in vivo compression load in the lumbar discs during daily activities are:

Natural Disc.during daily activities are:

Normal Standing up: 700 – 1000 NSt ndin up ith t unk fl x d 30º: 2400 NStanding up with trunk flexed 30º: 2400 NSitting: 1800 – 2700 NBending forward and lifting a 20 kg load: 4000-4200 N

Intradiscal compressive stresses (typical adult) during daily activities are:activities are

Standing: 0.2 – 1.1 MPaSitting: 0.4 – 1.5 MPaD i d i ht b i ti : t 2 5 MPDynamic and weight bearing motions: up to 2.5 MPaEstimated Young’s Modulus (from FEM models) for a nucleus is: up to 4.2 MPa( ) p

Page 12: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Polyurethane Material RequirementsGeneral PU ChemistryP l h i l l d

Polyurethane Material Requirements

Polyurethanes are a common commercial polymer and can possess diverse properties depending on how they are manufactured. They are characterized by containing the repeat unit:y g p

N O

O

PU’s generally have hard and soft segments. In one way, they can be considered both amides and esters of carbamic acid

NH

O

be considered both amides and esters of carbamic acid (carbamates). The repeat unit is usually synthesized by addition of an active hydrogen containing species across the carbon-nitrogen double bond of an isocyanate double bond of an isocyanate.

Page 13: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Isocyanate/Polyol Reaction Forming a Linear TPUa Linear TPU

A di functional isocyanate reacting with a diol will yield a linear andtherefore thermoplastic polyurethane, (TPU).

A medium Mw diol (~400-2500 Daltons) is reacted with the l l ll ldiisocyanate yielding a pre polymer as illustrated below.

2 O C N R NCO + HO OH7 0 - 9 0 o C

D i i s o c y a n a t e O l i g o - p o l y o l

OCN R NHCOO OOCNH R NCO

P r e p o l y m e r

By the reaction of the pre polymer with a chain extender such asethylene glycol, 1,4-Butane diol or a diamine, the high Mw polymer isformed.f

Page 14: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Typical Isocyanates for PU ManufactureManufacture

CH2 N=C=OO=C=N

Top left-1,6, hexamethylene di-isocyanate (HDI): middle-right-2, 4-Toluene isocyanate (TDI): middle-left; Isophorone diisocyanate: bottom-4,4’ methylene bis(phenyl isocyanate), MDI, and far right Hydrogenated MDI 4 4’ methylene bis(cyclohexane diisocyanate)right, Hydrogenated MDI, 4,4 methylene bis(cyclohexane diisocyanate).

Page 15: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Segmented PUSegmented PUThe urethane and/or urea linkages with the extender species, because of

the possibility of hydrogen bonding generate the “hard” domain or “hard the possibility of hydrogen bonding, generate the hard domain or hard segment” of the PU elastomer as illustrated below.

The high mobility of high Mw polyol chains represent the “soft segment” d th hi h l ti it f th lti PU l t Thi t t i and ensure the high elasticity of the resulting PU elastomer. This structure is

virtually cross linked by secondary (hydrogen) bonds. At higher temperatures the hydrogen bonds are destroyed and therefore at high temperatures it is possible to process the linear PU elastomers in the melt state similar to all

Hard Domain Soft Domain

possible to process the linear PU elastomers in the melt state, similar to all common thermoplastics.

CHN

HO

N CO

OH

HO

Hydrogen bonds

HO

C NN

OH

HO

C

HO

The hard and soft domains of PU elastomers

Page 16: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Soft Segment StructureStudies have shown that some PU elastomers (ester-based) were not

suitable for long term implantation due to poor hydrolytic stability [1] [2]

Soft Segment Structure

suitable for long term implantation due to poor hydrolytic stability.[1] [2]

The problem was thought to be addressed to some degree by the use of polyether macro diols. Polyteramethylene oxide (PTMO) macro diols being a favourite choice, but these are susceptible to oxidative degradation[3]. g

The degradation appears as surface cracking, stiffening and erosion or deterioration of the mechanical properties such as flex fatigue or deterioration of the mechanical properties such as flex fatigue resistance.

Bi d d ti l l d t l h bl t i d t Biodegradation may also lead to leachable toxic products.

Page 17: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Oxidative DegradationOxidative DegradationIt is likely that the biological chemical agents derived from the host implant response are oxidative and that susceptible functionalities implant response are oxidative and that susceptible functionalities such as abstractable methylene hydrogen atoms adjacent to oxygen in the PTMO macrodiol are the points of attack [4].

This theory is reinforced by the observation of enhance bio stability in the presence of antioxidants.

NH

O

O:CH

H

NH

O

O:CH

H

H O-

O CH3

+

NH OH

The siscion products may cross link to adjacent chains, therefore the TPU becomes harder and brittle, with a

+

change in Mw.

Page 18: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Polycarbonate Macro DiolsPolycarbonate Macro Diols

Use Polycarbonate diol as the soft segment.

Esterase Enzymic attack of the polycarbonate moiety has been y p y yreported.

However polycarbonate soft segments are thought to be the most p yattractive avenue for chronic bio stable PU implants.

The polycarbonate shows enhanced biostability over polyester p y y p yurethanes for two main reasons.

Page 19: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Stability of Carbonate GroupStability of Carbonate Group.(i) The polycarbonate has a pseudo π-bonding system, thus stabilising the carbonate moiety against attack as shown belowthe carbonate moiety against attack, as shown below.

O O

O O O O

The delocalised pi system for polycarbonate

(ii) H d l i f th b l i t i id t l d

The delocalised pi system for polycarbonate

(ii) Hydrolysis of the carbonyl moiety is acid catalysed.

Hydrolysis of an ester yields an alcohol and an acid, thus the reaction becomes self catalysed, whereas hydrolysis of the carbonate group yields CO2 and an alcohol, leading to slower reaction kinetics.

Page 20: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Stability of Carbonate Group (Cont )Stability of Carbonate Group (Cont.)

S h PU if it’ diffi lt t hi h i (50 ) • So why use PU if it’s so difficult to achieve chronic (50 yrs +) biostability?

• PU is used for it’s excellent mechanical versatility.

• The material’s bulk properties determines the specific mechanical requirements.

• The surface chemistry governs the biostability.

• Therefore modify surface to protect the vulnerable soft segment.

Page 21: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Self Assembling Monolayer End-Groups (SAME) (PTG)Groups (SAME)-(PTG).

Generally, a material is designed for its bulk properties but its y g p psurface chemistry is what determines the biocompatibility. SAME technology offers a solution to this problem.

SAMEs may be engineered into medical polymers during synthesis to provide a robust, built-in surface chemistry that self-assembles after device fabrication. More than one SAME may be used on a single polymer.

Therefore the bulk polymer may determine characteristics such as mechanical integrity while the SAME determines the surface bi t bilit biostability.

Page 22: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Self Assembling Monolayer End-Groups (SAME) (PTG) (cont )Groups (SAME)-(PTG). (cont.)

SAMEs have the advantage over self assembled monolayers (SAM) in that they are designed to covalently bond with the surface of the bulk polymer thus enabling in vivo environmental stability E g a bulk polymer, thus enabling in vivo environmental stability. E.g. a SAME-modified polycarbonate urethane using an octadecane end group.

This technology has been developed at the Polymer Technology Group (PTG) in Berkley, CA and may be one solution to long term bi st bilit /bi d bilitbiostability/biodurability.

Page 23: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

P f PAnother way of functionalising PU in order to provide an enhanced

Reactive Processing of PUAnother way of functionalising PU in order to provide an enhanced biostable and/or functionalised surface chemistry is to react the PU in the melt with various reactive species.

Epoxide ring opening followed by a siloxane exchange reaction.

O Si(OMe)3 O SiOSiMe3

Me3SiOO 0

OSiMe3+3HOSiMe3

+3MeOH3 3MeOH

Siloxane type materials show an enhanced biostability over conventional PU, thus the above reaction will ,

facilitate a PU with enhanced biostability.B.G.Willoughby

Page 24: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Reactive Processing of PU (cont )Reactive Processing of PU (cont.)As mentioned earlier, device migration under normal loading is a serious issue with a spinal nucleus prostheticserious issue with a spinal nucleus prosthetic.

It was thought that an acid surface would bind the TPCU implant to the amine groups of the portentous material of the annulus fibrosis the amine groups of the portentous material of the annulus fibrosis, thus anchoring the device in place.

OH

N

OH

SCO2H

mercaptoacetic acid

1. The reaction involves the N-H of the PU therefore temperaturesgreater than the Tm of the hard

N H N

OH

+

crotonic acid

1,2-epoxy-5-hexene

o

gsegment are required.

An epoxide ring opening reaction

N

OH

CO2H

followed by either mercapto aceticacid or crotonic acid may facilitatean acid surface, as shown.

Page 25: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Reactive Processing of PU (cont )Reactive Processing of PU (cont.)Anhydride Ring opening reaction.2. y g p g

The reaction of interest here is that of a cyclic anhydride, where ring opening by an active-hydrogen species (HX) gives a carboxylic acid pendant group.

OO O XO

OO

+HXO O

H

The reaction with a urethane N-H can be represented as follows:

OO ONH

OYO

N

OYO

O+OO ONH

z

NO

OOH

z

Page 26: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Reactive Processing of PU (cont )The Gale/ Smithers Rapra mini mixer was modified to facilitate a

l d ti t PU lt t t 180 220°C

Reactive Processing of PU (cont.)

sealed reaction at PU melt temperatures, 180<>220°C.

Page 27: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Thermoplastic PCU synthesisAn MDI-based polycarbonate Urethane was formulated in a two stage process targeting the previously mentioned mechanical

Thermoplastic PCU synthesis

stage process targeting the previously mentioned mechanical properties required for a nucleus prosthetic device.

Stage 1.gA 3:1 pre-polymer (NCO:OH) was prepared by reacting MDI (Sigma

Aldrich; used as received) with a mixture of two Mw oligomericHexamethylene carbonate diols; Mw 650 and Mw 2000 (Sigma Aldrich; dried y ( gunder vacuum for 8 hrs) blended in a 1:1 ratio by equivalent weight.

MDI was placed in a reaction vessel under a dry nitrogen stream and held between 70-80°C The polycarbonate diol mixture was added slowly over 40 between 70-80 C. The polycarbonate diol mixture was added slowly over 40 minutes under stirring.

Stage 2.gThe pre-polymer was chain extended with Butane diol (Sigma-Aldrich,

dried under vacuum for 8 hrs), yielding an overall stoichiometry of 1:1 NCO:OH, therefore yielding a thermoplastic PCU.

Page 28: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Results and Discussion:Sterilisation studiesSterilisation studies

The SRT TPCU was characterised pre and post electron beam sterilisation using the following techniques:

DMTA Th l E t•DMTA: Thermal Events.•FTIR: Functional Group.F IR Funct onal Group.•Mechanical Testing: Reduction in

ti s properties on sterilisation.

•GPC: Molecular weight Changes.Changes.

Page 29: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

DMTA Pre- and Sterilised SampleDMTA Pre- and Sterilised SamplePolyurethane PUMCC2-99

Scales Not UKAS Calibrated

1.2E+09 0.61 Hz PeakTemperature (C)=-10.9

10 Hz PeakTemperature (C)=-6.4

6.0E+08

8.0E+08

1.0E+09

Mod

ulus

(Pa)

0.3

0.4

0.5

Tan Delta Modulus 1.

Modulus 10.Tan Delta1.Tan Delta10.

Pre-Sterilisation

0.0E+00

2.0E+08

4.0E+08

-100 -50 0 50 100 150

Temperature (C)

0

0.1

0.2

PUMCC2-B99(ii) Scales Not UKAS Calibrated

1.0E+09

1.2E+09

0.5

0.6

1 Hz Peak Temperature (C)=-10.3

10 Hz Peak Temperature (C)=-5.5 e- beam sterilised.25 kG

6.0E+08

8.0E+08

Mod

ulus

(Pa)

0.3

0.4

Tan

Del

ta Modulus 1.Modulus 10.Tan Delta1.Tan Delta10.

25 kGy

0 0 00

2.0E+08

4.0E+08

M

0

0.1

0.2

0.0E+00-100 -50 0 50 100 150

Temperature (C)

0

Page 30: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

FTIR-Golden GateFTIR Golden Gate

80

85

90

JN0006-04.Via S Rowlands. Golden gate IR of fresh cut surface of PUMCC'B-99 sample as received.HFAV25743

80

85

JN0006-04. Research Projects. Golden Gate IR of (1) PUMCC2 - B99(ii) fresh cut surface as received. BH.AV25899

55

60

65

70

75

80

ctan

ce 55

60

65

70

75

ctan

ce

30

35

40

45

50

55

%R

efle

c

30

35

40

45

50

%R

efle

cSmithers Rapra Collection time: Thu Jun 11 12:25:37 2009

20

25

30

800 1000 1200 1400 1600 1800 2000 2000 2500 3000 3500 4000 Wavenumbers (cm-1)

Smithers Rapra Collection time: Thu Jul 02 08:36:13 2009

15

20

25

800 1000 1200 1400 1600 1800 2000 2000 2500 3000 3500 4000 Wavenumbers (cm-1)

Smithers Rapra Collection time: Thu Jun 11 12:25:37 2009 Smithers Rapra Collection time: Thu Jul 02 08:36:13 2009

Pre-sterilisation Post-Sterilisation

Page 31: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Mechanical TestingMechanical TestingMaximum Tensile Strength (MPa)

Sample1 2 3 4 5 Median

Unsterilised PU 16.6 10.4 15.2 10.6 10.8 10.8S ili d 4 3 0 3 3 0Sterilised PU 11.1 14.1 13.0 11.5 15.3 13.0

100% Modulus (MPa)

Sample1 2 3 4 5 Median

Sample

Unsterilised PU 9.34 7.91 8.92 8.05 8.23 8.23Sterilised PU 8.10 8.30 8.20 8.20 8.30 8.20

200% Modulus (MPa)200% Modulus (MPa)

Sample1 2 3 4 5 Median

Unsterilised PU 12.34 9.38 11.38 9.62 9.91 9.91Unsterilised PU 12.34 9.38 11.38 9.62 9.91 9.91Sterilised PU 9.7 10.5 10.4 10.0 10.8 10.4

Page 32: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Mechanical Testing (cont.)T St th (N/ )Tear Strength (N/mm)

Sample 1 2 3 MedianUnsterilised PU 61.2 59.0 60.8 60.8

Sterilised PU 61.2 59.8 61.8 61.2

Shore A Hardness (3 second)Shore A Hardness (3 second)

Sample 1 2 3 4 5 Median

Unsterilised PU 89 80 90 90 91 90Sterilised PU 91 89 89 90 91 90

Page 33: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Mechanical Testing (cont.)Shore A Hardness (15 second)

1 2 3 4 5 M diSample

1 2 3 4 5 Median

Unsterilised PU 90 90 90 90 90 90Sterilised PU 90 88 89 89 90 89Sterilised PU 90 88 89 89 90 89

Unsterilised PU

Test No. Compression Modulus @ 10% Compression Modulus @ 20% (MPa) (MPa)

1 13.3 23.8

2 16.5 26.4

3 15.8 25.6

M 15 2 25 3Mean 15.2 25.3

Page 34: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

GPC: Chromatographic Conditions for PU Investigationsfor PU Investigations

Instrument: Polymer Laboratories PL-GPC 120 with PL-AS-MT auto sampler.

Columns: PL gel guard plus 2 x mixed-B, 30 cm, 10 µm,

Solvent: N,N’-dimethyl formamide with 0.01M lithium bromide,

Flow-rate: 1.0 mL/min (nominal),

T t PL GPC 120 80°C ( i l)Temperature: PL-GPC 120: 80°C (nominal),

PL-AS-MT: 80°C (nominal),

Detector: Refractive index.

Standards: PMMAStandards: PMMA.

Page 35: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

GPC Trace For Sterilised And Un Sterilised TPCUUn Sterilised TPCU

1 05

1.1

1. 15

1.2

MOLECULAR WEIGHT DISTRIBUTIONSPUMCC2-B99 pre-sterilisation

PUMCC2-B99 pre-sterilisation

PUMCC2-B99 (ii) Post-Sterilised

0.8

0. 85

0.9

0. 95

1

1. 05

M

PUMCC2-B99 (ii) Post-Sterilised

0.5

0. 55

0.6

0. 65

0.7

0. 75

dw/d

logM

0 2

0. 25

0.3

0. 35

0.4

0. 45

1 00 0 10 00 0 10 00 00 1 e6

0

0. 05

0.1

0. 15

0.2

Molecular Weight

Page 36: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

SummarySummaryAn aromatic polycarbonate Urethane (PCU), of shore 90A hardness was prepared hardness was prepared.

The PCU was electron beam sterilised by Custom-IMD ypartner LasMed with a dosage of 25 kGy.

The PCU was characterised pre and post sterilisation in The PCU was characterised pre- and post sterilisation in order to determine any detrimental effects of the sterilisation technique on the PCU.

No significant changes were observed pre and post sterilisationsterilisation.

Therefore e -beam sterilisation is an appropriate sterilisation h d f h f lmethod for this type of material.

Page 37: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

SummarySummary

S i l th i i t h i ll h ll i • Spinal prosthesis is technically challenging, PU used for it’s Bulk mechanical properties.p p

P l b t s ft s m t s d f • Polycarbonate soft segment used for enhanced biostability.

• An aromatic polycarbonate Urethane (PCU) • An aromatic polycarbonate Urethane (PCU), of shore 90A hardness was prepared.

Page 38: Biomedical Polyypurethane Developed Within the Custom-IMD ... IMD... · Smithers Rapra TechnologySmithers Rapra Technology. Contents 1. Introduction to the Custom IMD Project. 2

Further InformationFurther Information

For further information on Custom IMD and the technical developments made within the project, you can access the

project training materials which are available on the project training materials, which are available on the Extended Services website. Please visit: www.customimd.eu

and click on the link to the ‘Extended Services’ webpage.

The Custom IMD project is supported by funding under the Sixth Framework Programme of the European Union.

Contract No: 026599.Contract No 026599.